OncoLink

Thank you so much for publishing an article on OncoLink [F. Hoke, The Scientist, April 3, 1995, page 1]. I thought it was a good, balanced report. I believe that a quality future for OncoLink, or OncoLink by another name, will happen only if discussion concerning OncoLink has a good media forum. Thank you for providing such a forum. I don't believe that the present editors of OncoLink understand the dynamics necessary to keep OncoLink current and responsive to patients' needs. They envisioned

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

I believe that a quality future for OncoLink, or OncoLink by another name, will happen only if discussion concerning OncoLink has a good media forum. Thank you for providing such a forum.

I don't believe that the present editors of OncoLink understand the dynamics necessary to keep OncoLink current and responsive to patients' needs. They envisioned themselves primarily as editors or reviewers. Essentially this is a passive role. OncoLink attained its former status because Loren Buhle did not operate in a passive role. By reading Internet Usenet and mailing/discussion lists and by participating in the CompuServe cancer forum, he stayed informed about patients' most urgent concerns. A concept of what material is needed and the dedication to find such material is part of what Buhle provided. In addition, he provided that information in a timely manner.

In my opinion, OncoLink is currently becoming stale. As time goes, I am guessing ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Linda Yarger

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours